Full steam ahead at F2G
The UK developer has the launch of what could be the first in a new class of antifungals in its sights.
Spero proves a canny dealmaker – again
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
Go or no go? Bristol’s Tyk2 test
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
